PT-141 Benefits: Evidence, Verdict, and Limits
PT-141 has its strongest evidence for Female Sexual Desire, Nausea, and Male Erectile Function. ExaminePeptides rates the overall file Level A and classifies the current research status as FDA Approved. PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire disorder in premenopausal women (Vyleesi), providing a regulatory anchor for sexual health research. Phase 3 data in women is solid; male sexual dysfunction data is earlier-stage. For melanocortin-pathway sexual health research, this is the best-evidenced starting point.
Direct Answer
PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire disorder in premenopausal women (Vyleesi), providing a regulatory anchor for sexual health research. Phase 3 data in women is solid; male sexual dysfunction data is earlier-stage. For melanocortin-pathway sexual health research, this is the best-evidenced starting point.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Sexual Health
- Best for
- Hypoactive sexual desire disorder (women), sexual dysfunction research, melanocortin pathway
Best-Supported Benefits
- Female Sexual Desire: Level A, includes human evidence - FDA-approved based on Phase 3 trials showing statistically significant increase in sexual desire and reduction in distress related to low sexual desire in premenopausal women.
- Male Erectile Function: Level B, includes human evidence - Clinical trials demonstrated efficacy in male erectile dysfunction, including cases non-responsive to PDE5 inhibitors. Not FDA-approved for this indication.
- Nausea: Level A, includes human evidence - Nausea is the most common side effect, affecting ~40% of users. Usually mild to moderate and transient.
Evidence Quality
PT-141 is rated Level A. The current research status is FDA Approved. Stronger human evidence is separated from animal, cell, or early-stage findings.
Safety Context
- Contraindicated in uncontrolled hypertension
- May cause transient BP increase
- Limit to 8 doses per month
- Risk of hyperpigmentation with frequent use
- Nausea may be significant
Primary Sources
- Bremelanotide for Female Sexual Dysfunction (RECONNECT Phase 3). Obstet Gynecol, 2019.
- Bremelanotide for male sexual dysfunction. Int J Impot Res, 2006.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Female Sexual Desire (Level A), Nausea (Level A), and Male Erectile Function (Level B) |
| Primary citation count | 2 |
| Last reviewed | 2026-06-02 |
Related Guides
How to Cite This Page
ExaminePeptides. "PT-141 Benefits: Evidence, Verdict, and Limits." Last reviewed 2026-06-02. https://examinepeptides.com/answers/pt-141-benefits-evidence/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.